Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route
Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route
Background:

 Influenza (flu) is a contagious respiratory virus that makes humans sick. Usually its
 symptoms are mild, but they can be dangerous. Researchers want to see if one way of giving
 the flu vaccine is more effective than another.

 Objective:

 To compare the body s ability to fight infection when a flu vaccine is given in the nose
 versus the arm.

 Eligibility:

 Healthy, nonsmoking adults ages 18 55. They must be willing to stay in isolation for at least
 9 days. They must not have had the flu vaccine since September 1, 2018.

 Design:

 Participants must be willing to use birth control or abstinence from visit 1 until 8 weeks
 after getting the flu virus.

 Participants will have at least 3 clinic visits over about a month. Visits may include:

 Medical history

 Physical exam

 Blood and urine tests

 Nasal samples collected

 Heart and lung function tests

 At the first visit, participants will get either:

 Flu vaccine as injection in an arm muscle plus salt water sprays in the nose

 OR flu vaccine as sprays in the nose plus salt water injection in an arm

 Within the next few months, participants will stay in an isolation room for at least 9 days.
 They will be with up to 20 participants. Those who test positive for recreational drugs will
 leave the study. Participants will:

 Repeat study tests

 Answer questions about flu symptoms

 Have the flu virus sprayed into their nose once

 Be monitored by a medical team

 Participants will have at least 2 follow-up visits and repeat study tests.
The high morbidity and mortality associated with both pandemic and seasonal influenza and the
 threat of new potentially pandemic strains emerging makes influenza an important infectious
 disease and public health problem. Public health agencies must continue attempts to reduce
 the public health impact of this important virus.

 Currently, influenza vaccination is the cornerstone of prophylaxis and the most effective
 method available to reduce the impact of influenza on the population. Current vaccines target
 the major surface protein, hemagglutinin (HA), and are standardized by stimulation of serum
 anti-HA antibodies as the primary correlate of protection. Measurements of serum antibodies
 to HA have become the gold standard for evaluating vaccines. The Food and Drug Administration
 (FDA) and the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use
 (CHMP) both define protective titers as a hemagglutination inhibition (HAI) titer of greater
 than or equal to 40. Recent vaccine effectiveness has been limited and, in some populations,
 estimated at as low as 10%. Improved methods of vaccination must be developed, but limited
 information regarding the true correlates of protection is available. Correlates of
 protection in the systemic circulation may be less informative than those located in the
 nasopharyngeal mucosa, which is the site of exposure to and infection with influenza virus.

 This study is designed to characterize the mucosal and systemic immunologic correlates of
 protection from influenza infection in persons vaccinated and unvaccinated against influenza.
 Half of participants will receive current licensed quadrivalent inactivated influenza vaccine
 (IIV) administered via the intramuscular (IM) route at the standard dose, prior to challenge
 with influenza virus. The other half will receive no vaccination prior to challenge.
 Immunologic response and clinical outcomes in the human challenge model will be determined to
 characterize the two cohorts. In the vaccinated cohort, mucosal and systemic immune responses
 induced by IM administration of quadrivalent IIV will also be carefully explored. The
 thoughtful study of mucosal immunity to influenza is expected to identify novel correlates of
 protection. By administering quadrivalent IIV and then infecting participants with human
 challenge virus, we can evaluate in detail the immunologic responses after immunization and
 subsequent virus exposure. This controlled setting offers the ideal environment to query
 these responses and to identify targets of mucosal stimulation for future vaccine strategies.
 In addition, the detailed characterization of the mucosal and systemic immune responses after
 vaccination and challenge will represent a true advance in understanding influenza immunity.
-  INCLUSION CRITERIA:

 1. Greater than or equal to 18 and less than or equal to 55 years of age.

 2. Non-smoker.

 3. Have not received influenza vaccination of any type (whether licensed or
 unlicensed experimental vaccine) on or after September 1, 2018. Participants who
 enroll in our study must be informed of the Centers for Disease Control and
 Prevention (CDC) recommendation to receive seasonal influenza vaccination
 annually. Enrollees accept that half of study participants will receive licensed
 approved vaccination per the usual route, and half will receive it by an
 unapproved route with unknown efficacy and side effects. Enrollees should not
 plan to receive seasonal influenza vaccination from another source from
 enrollment through the final study visit (Phase 2, Day 56).

 4. Willingness to remain in isolation for the duration of viral shedding (at a
 minimum 9 days) and to comply with all study requirements.

 5. A male subject is eligible for the study if he meets one of the following
 criteria, beginning at least 4 weeks prior to enrollment and continuing until 8
 weeks after administration of the human challenge virus:

 1. Is infertile, including history of successful vasectomy.

 2. Agrees to practice abstinence.

 3. Agrees that, with heterosexual intercourse with a fertile female partner, he
 will use a condom with spermicide and his female partner (including those
 who have undergone bilateral tubal ligation) will use an acceptable form of
 contraception (see inclusion criterion 6c).

 6. A female participant is eligible for this study if she is not pregnant or
 breastfeeding and meets one of the following criteria, beginning at least 4 weeks
 prior to enrollment and continuing until 8 weeks after administration of the
 human challenge virus::

 1. infertile, including postmenopausal status, (as defined by no menses for
 greater than or equal to 1 year) or history of hysterectomy.

 2. Agrees to practice abstinence.

 3. Agrees that, with heterosexual intercourse with a fertile male partner, she
 will use an acceptable form of contraception and her male partner will use a
 condom with spermicide. Acceptable effective methods of female contraception
 include the following: bilateral tubal ligation, implant of levonorgestrel,
 injectable progestogen, intrauterine device oral contraceptive pills and
 diaphragm with spermicide.

 7. Willing to have samples stored for future research.

 8. HIV uninfected with a negative test within 60 days of Phase 2, Day 0.

 9. Agrees not to use IN medications (including but not limited to nasal

 sprays, sinus rinses), over-the-counter medications (including but not

 limited to aspirin, decongestants, antihistamines, and other non-steroidal
 anti-inflammatory drugs), and herbal medications (including but not limited to
 herbal tea or St. John s Wort), from 14 days prior to study enrollment through
 the final study visit (Phase 2, Day 56), unless approved by the investigator

 10. Agrees not to donate blood or blood products from enrollment through the final
 study visit (Phase 2, Day 56).

 EXCLUSION CRITERIA:

 1. Presence of self-reported or medically documented significant medical condition
 including but not limited to:

 1. Chronic pulmonary disease (e.g., asthma, emphysema).

 2. Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure,
 cardiac surgery, ischemic heart disease, known anatomic defects).

 3. Chronic medical conditions requiring close medical follow-up or hospitalization
 during the past 5 years (e.g., insulin-dependent diabetes mellitus, renal
 dysfunction, hemoglobinopathies).

 4. Immunosuppression, immune deficiency (such as IgA deficiency) or ongoing
 malignancy.

 5. Neurological and neurodevelopmental conditions (e.g., Bell s palsy, cerebral
 palsy, epilepsy, stroke, seizures).

 6. Postinfectious or postvaccine neurological sequelae including Guillain Barre
 syndrome.

 7. Individual with body mass index less than or equal to 18 and greater than or
 equal to 40.

 2. Have close or household (i.e., share the same apartment or house) high-risk contacts
 including but not limited to:

 1. Persons greater than or equal to 65 years of age.

 2. Children less than or equal to 5 years of age.

 3. Residents of nursing homes.

 4. Persons of any age with significant chronic medical conditions such as:

 -  Chronic pulmonary disease (e.g., severe asthma, chronic obstructive
 pulmonary disease).

 -  Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart
 failure, cardiac surgery, ischemic heart disease, known anatomic defects).

 -  Contacts who required medical follow-up or hospitalization during the past 5
 years because of chronic metabolic disease (e.g., insulin-dependent diabetes
 mellitus, renal dysfunction, hemoglobinopathies).

 -  Immunosuppression or cancer.

 -  Neurological and neurodevelopmental conditions (e.g., cerebral palsy,
 epilepsy, stroke, seizures).

 -  Individuals who are receiving long-term aspirin therapy.

 -  Women who are pregnant or who are trying to become pregnant.

 3. Acute illness within 7 days prior to quadrivalent IIV administration or inoculation
 with the human challenge virus.

 4. Individuals who have grade 3 or above clinically significant laboratory values outside
 the limits thus specified by normal laboratory parameters.

 5. Clinically significant abnormality as deemed by the PI on echocardiographic (ECHO)
 testing.

 6. Clinically significant abnormality as deemed by the PI on the pulmonary function test
 (PFT).

 7. Known allergy to influenza vaccination or excipients contained in the influenza
 vaccine used.

 8. Known allergy to lidocaine or phenylephrine.

 9. Known allergy to treatments for influenza (including but not limited to oseltamivir or
 nonsteroidal anti-inflammatory medications).

 10. Known allergy to 2 or more classes of antibiotics (e.g., penicillins, cephalosporins,
 fluoroquinolones, or glycopeptides).

 11. Anatomic or functional defects of the nasopharynx that could affect nasal sampling
 such as chronic rhinitis, nasal septal defect, nasal polyps or recent or remote nasal
 surgery

 12. Receipt of blood or blood products (including immunoglobulins) within 3 months prior
 to enrollment.

 13. Donation of blood or blood products within 3 months prior to study enrollment.

 14. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is
 greater) prior to enrollment.

 15. Receipt of any unlicensed vaccine within 6 months prior to enrollment.

 16. Self-reported or known history of alcoholism or drug abuse within 6 months prior to
 enrollment, or positive urine test for drugs of abuse (i.e., amphetamines, cocaine,
 benzodiazepines, opiates, metabolites, or tetrahydrocannabinol) at time of admission
 for viral challenge.

 17. Self-reported or known history of psychiatric or psychological issues that require
 treatment and are deemed by the PI to be a contraindication to protocol participation.

 18. Any condition or event that, in the judgment of the PI, is a contraindication to
 protocol participation or impairs the participant s ability to give informed consent.